



Supplemental Figure 1. Schedule of treatment regimes, biodistribution time points and SPECT imaging time points of mice bearing FaDu xenografts treated with bevacizumab (A), SK-RC-52 xenografts treated with bevacizumab (B), FaDu xenografts treated with sorafenib (C), or with local irradiation (D).